medicina61巻1号

2024年01月発行

特集 その知見は臨床を変える?—エキスパートが解説! 内科における最新論文

腎臓

保存期の末期腎不全（ESKD）に対するRAS阻害薬の中止が腎不全の進行に及ぼす影響

著者： 北野史也¹ 緒方聖友¹

所属機関： ¹聖マリアンナ医科大学腎臓・高血圧内科

ページ範囲：P.107 - P.111

文献概要

Point
◎保存期末期腎不全（ESKD）患者におけるRAS阻害薬の中止について，STOP-ACEi試験をもとに検討した．
◎腎不全進展抑制について中止/継続で有意差はみられず，本剤の中止は許容される場合がある．
◎本剤中止による心血管イベントの増加については不明確だが，血清K高値例での中止は検討される．
◎本剤の中止/継続は，有害事象の発生リスクに注意して総合的に判断する．

参考文献

1）Eijkelkamp WB, et al：Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy；Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin Ⅱ Antagonist Losartan（RENAAL）trial. J Am Soc Nephrol 18：1540-1546, 2007 PMID 17409317

2）Edmund JL, et al：Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345：851-860, 2001 PMID 11565517

3）Matsumori A；Assessment of Response to Candesartan in Heart Failure in Japan（ARCH-J）Study Investigators：Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5：669-677, 2003 PMID 14607207

4）Dickstein K, Kjekshus J；OPTIMAAL Steering Committee of the OPTIMAAL Study Group：Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction；The OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Losartan. Lancet 360：752-760, 2002 PMID 12241832

5）Ferrari R：RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract 2013：269-278, 2013 PMID 24689028

6）Giuseppe R, et al：The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 99：S57-S65, 2005 PMID 16336578

7）Ma TK, et al：Renin-angiotensin-aldosterone system blockade for cardiovascular diseases；Current status. Br J Pharmacol 160：1273-1292, 2010 PMID 20590619

8）Bhandari S, et al：Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387：2021-2032, 2022 PMID 36326117

9）Fu EL, et al：Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes；A nationwide study. J Am Soc Nephrol 32：424-435, 2021 PMID 33372009

10）O'Hare AM, et al：Interpreting treatment effects from clinical trials in the context of real-world risk information；End-stage renal disease prevention in older adults. JAMA Intern Med 174：391-397, 2013 PMID 24424348

11）Hundemer GL, et al：Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence. Clin J Am Soc Nephrol 16：365-373, 2021 PMID 33608262

12）Kohsaka S, et al：Risk-benefit balance of renin-angiotensin-aldosterone inhibitor cessation in heart failure patients with hyperkalemia. J Clin Med 11：5828, 2022 PMID 36233692

13）Kidney Disease；Improving Global Outcomes（KDIGO）Blood Pressure Work Group：KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99：S1-S87, 2021 PMID 33637192

14）Hirai T, et al：Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin Ⅱ receptor blockers treatments. J Clin Pharm Ther 43：829-835, 2018 PMID 29908131

15）日本腎臓学会（編）：エビデンスに基づくCKD診療ガイドライン2023. pp127-128，東京医学社，2023